Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Oral Hygiene Products on Reducing Expelled/Exhaled SARS-CoV-2
NCT04931004Phase 1Completed
- Sponsor
- Rutgers University
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Conventional Liposomes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of cetylpyridinium chloride in coronavirus disease 2019 (COVID-19), sponsored by Rutgers University. Primary endpoints: Control Phase - Primary Endpoint at 1 hour and Evaluation Phase - Primary Endpoint at 1.5 hours. Started Jul 2021; status: completed.
02
Drugs
cetylpyridinium chloride
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04931004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931004.